Petronas Chemicals budgets $6B for specialty portfolio deals

June 25, 2019

The chemicals arm of Malaysia’s state energy firm Petronas plans to spend roughly $6 billion over the next 15 to 20 years to expand its specialty chemicals portfolio through acquisitions and partnerships, the unit’s chief exe cutive said. The budget is part of Petronas Chemicals Group Bhd’s efforts to make high-margin specialty chemicals a central part of its business, Sazali Hamzah said in an interview with Reuters at the Asia Oil & Gas Conference. “By doing that we are going to diversify our portfolio and our dependency on crude and gas will be a lot less,” he said. Petronas Chemicals has been looking to grow rapidly in specialty chemicals, which are raw materials used to manufacture consumer products such as high-performance tyres, medical gloves and LED televisions. Other major oil companies such as Saudi Aramco have also been expanding into petrochemicals in recent years to diversify from crude oil production. In May, Petronas Chemicals acquired Netherlands-based Da Vinci Group BV for 163 million euros ($186 million) in the first acquisition of its specialty chemicals push. An immediate growth area for the company is the Refinery and Petrochemical Integrated Development (RAPID) business, a 50-50 partnership with Saudi Aramco in the southern Malaysian state of Johor.

Spotlight

Heritage Pharmaceuticals Inc.

Heritage Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centres of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

OTHER ARTICLES

Transporting biological and chemical materials - what you need to know

Article | February 13, 2020

The landscape of biological and chemical logistics has changed rapidly - as have the regulatory frameworks around it. What has not necessarily kept pace is the end-user understanding of the nature of these logistical processes, their opportunities and their constraints. Twenty years ago, the transmission of biological and chemical materials was limited to a small range of organisations: usually national and international research companies, hospitals, major university departments, police and military departments with forensic responsibilities.

Read More

Setting record straight on testing harm in chemicals

Article | February 13, 2020

The modern world is built on chemicals, be it the medicines we use, or cleaning fluids, crop protection products, or the raw materials for everything from laptops and mobile phones to clothes and furniture. Across all, we have created an entire modern society with chemicals, and, as a result, constantly stretched the size of the world population we can feed, clothe and shelter. Yet, balancing all the gains from the modern chemistry around us against any negative environmental and human impact has been a rising concern, making for ever greater focus on testing and on risk assessment.

Read More

Why chemical characterization is the best way to assess patient risk

Article | February 11, 2020

Everyone is very familiar with the phrase when buying a house: All that really matters are three things - location, location, and location. This same principle applies to extractables and leachables chemistry analysis – the three things that truly matter are identification, identification, and identification. The greatest growth in the past ten years in demonstrating the safety of medical devices and container closure systems for drugs has been using analytical chemistry to determine what chemicals can leach from the device and what the patient is exposed to during its intended use.

Read More

How Chemical Companies Benefit from the Experience Economy

Article | February 10, 2020

To feel or experience from a business engagement started with customer experience mainly in the consumer products business. Today it has extended to even knowledge industries like the chemical industry where experiencing or feeling can be leveraged to include all stake holders from customers primarily to employees to supply chain people & suppliers and all else. With digital technologies this has become easier than before. The benefits from promoting the ‘feel’ or ‘experience’ emotion could be multifarious for the chemical industry as described in this article.

Read More

Spotlight

Heritage Pharmaceuticals Inc.

Heritage Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic pharmaceutical products for the global prescription drug markets. Heritage Pharmaceuticals provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions. Our global supply chain network is built around centres of manufacturing and scientific excellence to provide you with the highest level of quality, safety, value and service in generics. Our drug portfolio consists of numerous products across a wide range of therapeutic categories, including: cardiovascular, oncology, metabolic disease, anti-infective, infusion and pain management. We are focused on widely utilized, established products as well as niche, high barrier-to-entry products that have limited competition and long life cycles.

Events